Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05873439 | Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC | completed | Early Phase 1 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04298606 | A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence | completed | Early Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04049474 | Bronchoscopic Cryo-Immunotherapy of Lung Cancer | completed | Early Phase 1 | 21 | NYU Langone HealthOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT02978196 | 99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC | completed | Early Phase 1 | 34 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT01383135 | Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 | completed | Early Phase 1 | 27 | Stanford UniversityOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03858491 | Pharmacokinetic Boosting of Osimertinib(OSIBOOST) | completed | Early Phase 1 | 11 | Academisch Ziekenhuis MaastrichtOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT01781741 | Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Early Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT03158883 | UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients | completed | Early Phase 1 | 8 | Megan Daly, MDOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02357836 | Neoadjuvant Itraconazole in Non-small Cell Lung Cancer | completed | Early Phase 1 | 13 | University of Texas Southwestern Medical CenterOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03224871 | UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. | completed | Early Phase 1 | 3 | University of California, DavisOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02628080 | Atovaquone as Tumour HypOxia Modifier(ATOM) | completed | Early Phase 1 | 46 | University of OxfordOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT01666353 | PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT02463994 | A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | completed | Early Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT00221169 | Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer | completed | Early Phase 1 | 31 | Toronto Sunnybrook Regional Cancer CentreOTHER | 1 | Feb 5, 2009 | clinicaltrials |
Data updated 23 days agoSource updated Apr 1, 2026source: clinicaltrials